3 completed, 3 terminated, 2 unknown, 1 recruiting. 7 Phase 2, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 3, Terminated 2, Unknown 2 |
| Not applicable | 1 | Recruiting 1 |
| Phase 1 | 1 | Terminated 1 |
Follow Small Cell Lung Cancer Recurrent: new trials by email Literature Review of Small Cell Lung Cancer Recurrent trials Research Report on Small Cell Lung Cancer Recurrent
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer JS004, Toripalimab, Etoposide - Small Cell Lung Cancer Extensive Stage, Small Cell Lung Cancer Recurrent | Phase 2 | Completed | Shanghai Pulmonary Hospital, Shanghai, China | 100 | 2024-11-18 | 2026-10-15 |
| Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC Irinotecan Liposome, Anlotinib - Small Cell Lung Cancer Recurrent | Not applicable | Recruiting | Fudan University | 39 | 2024-04-17 | 2025-08-20 |
| Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy Debio 0123, Etoposide, Carboplatin - Small Cell Lung Cancer Recurrent | Phase 1 | Terminated | Debiopharm International SA | 34 | 2023-05-02 | 2026-05-04 |
| KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer KRT-232 - Small-cell Lung Cancer, Small Cell Lung Carcinoma | Phase 2 | Terminated | Kartos Therapeutics, Inc. | 3 | 2021-12-06 | 2023-08-16 |
| Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC PD-1 inhibitor, Metformin - Small-cell Lung Cancer, Small Cell Lung Carcinoma | Phase 2 | Unknown | Hunan Cancer Hospital | 68 | 2019-08-20 | 2019-08-28 |
| S1 Plus Anlotinib in Treating Patients With Refractory or Relapsed Small-cell Lung Cancer S1/Anlotinib - Small Cell Lung Cancer Recurrent | Phase 2 | Completed | Taizhou Hospital | 48 | 2019-03-01 | 2023-02-23 |
| Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for SCLC Atezolizumab - Small Cell Lung Cancer Recurrent | Phase 2 | Unknown | National Cancer Center, Korea | 35 | 2018-01-22 | 2022-04-06 |
| Temozolomide in Patients Affected by Relapsed Sensitive or Refractory Small Cell Lung Cancer With MGMT Methylation Temozolomide - Small Cell Lung Cancer Recurrent | Phase 2 | Terminated | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 6 | 2015-01-01 | 2018-11-13 |
| BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer BIBF 1120 - Small Cell Lung Cancer, Small Cell Lung Cancer Recurrent | Phase 2 | Completed | Ji-youn Han | 24 | 2011-12-01 | 2017-08-25 |
Small Cell Lung Carcinoma (6) · Recurrence (2)
Bronchial Neoplasms (6) · Carcinoma, Bronchogenic (6) · Lung Diseases (6) · Lung Neoplasms (6) · Neoplasms (6) · Neoplasms by Site (6) · Respiratory Tract Diseases (6) · Respiratory Tract Neoplasms (6) · Thoracic Neoplasms (6) · Disease Attributes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2)
Etoposide (2) · Carboplatin (1) · Immune Checkpoint Inhibitors (1) · Metformin (1) · Platinum (1) · Temozolomide (1) · anlotinib (1) · atezolizumab (1) · irinotecan sucrosofate (1) · navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid (1) · nintedanib (1) · sintilimab (1) · toripalimab (1)
Debiopharm International SA (1) · Fudan University (1) · Hunan Cancer Hospital (1) · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS (1) · Ji-youn Han (1) · Kartos Therapeutics, Inc. (1) · National Cancer Center, Korea (1) · Shanghai Pulmonary Hospital, Shanghai, China (1) · Taizhou Hospital (1)
China (4) · South Korea (3) · Spain (2) · United States (2) · Australia (1) · France (1) · Germany (1) · Hungary (1) · Italy (1)
Claudia Casanova, MD (1) · Ji-Youn Han, Ph.D. (1) · Ji-Youn Han, PhD. (1) · Jialei Wang, Doctor (1) · Lin Wu (1)